Myriad Genetics promotes Nicole Lambert to COO effective Jan 1, 2022

MYRIAD GENETICS INC

Appointed COO effective Jan 1, 2022; previously Group President over Oncology, Women's Health, International.
Received one-time award of 10,000 time-based RSUs vesting over 4 years; base salary increased to $499,963.
Lambert has 20-year tenure at Myriad; also serves on board of Arcus Biosciences (NYSE: RCUS).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicole Lambert

Chief Operating Officer

MYGN · MYRIAD GENETICS INC

Effective: 2022-01-01
Filed: December 14, 2021, 6:59 PM ET

On December 14, 2021, Myriad Genetics, Inc. (the “Company”) announced that Nicole Lambert, currently serving as its Group President, Myriad Women's Health, Oncology and International, has been appointed Chief Operating Officer of the Company, effective January 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole Lambert was appointed as Chief Operating Officer at MYRIAD GENETICS INC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On December 14, 2021, Myriad Genetics, Inc. (the “Company”) announced that Nicole Lambert, currently serving as its Group President, Myriad Women's Health, Oncology and International, has been appointed Chief Operating Officer of the Company, effective January 1, 2022.

View on SEC.gov

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-21-000097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.